This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

The progress in aplastic anaemia (AA) management is one of success. Once an obscure
entity resulting in death in most affected can now be successfully treated with either …

Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …

Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …

Pretreatment blood counts, particularly an absolute reticulocyte count≥ 25× 10 9/L,
correlate with response to immunosuppressive therapy in severe aplastic anemia. In recent …

Since the approval of horse antithymocyte globulin (ATG) decades ago, there was a long
hiatus in therapies with activity in severe aplastic anemia (SAA). This scenario changed in …

In the absence of an HLA-matched donor, the best treatment for acquired aplastic anemia
patients refractory to immunosuppression is unclear. We collected and analyzed data from …

Eltrombopag is an orally available thrombopoietin receptor agonist indicated for the
treatment of immune thrombocytopenia (ITP). Beyond the effect on megakaryopoiesis, the …

Outcomes remain poor for refractory severe aplastic anemia (SAA) patients. Alternative
donor transplantation may be considered, but results from previous studies are not …